<DOC>
	<DOCNO>NCT00561964</DOCNO>
	<brief_summary>To evaluate effect safety irbesartan proteinuria hypertensive patient type â…¡diabetes mellitus .</brief_summary>
	<brief_title>Randomized , Parallel , Comparison , Double-Blind Efficacy &amp; Safety Study APROVEL Versus Placebo Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Fasting plasma glucose untreated type II diabetes mellitus patient great equal 7.0 mmol/L , time diagnosis type II diabetes mellitus treatment &gt; 3 month The patient normal BP , hypertensive patient receive antihypertensive medication , Seated systolic blood pressure ( SeSBP ) 120180mmHg Seated diastolic blood pressure ( SeDBP ) 80110mmHg ; Evidence albuminuria define AER 20 500 ug/minute single time overnight collection . Before randomization patient must quality two AERs 3 day interval absence confound factor urinary tract infection , acute febrile illness cardiac failure . The two AERs measurement define range variability two AERs measurement must &lt; 35 % . Value basal AER calculate mean 2 measurement . The UAER measure use immunity nephelometer method ( DCA2000 ) ; Serum creatinine &lt; 150umol/L ( 1.7mg/dl ) serum potassium normal lab range ( 3.55.5 mol/L ) ; 18 Kg/m2less equal BMI le equal 35Kg/m2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>